August 12, 2020; This article by Dr Thomas Levy is really an expose’ and indictment (and they should be indicted) of governmental agencies and drug manufacturers working in collusion to generate massive profits for mainstream medicine. Most people have forgotten that God created Mankind from the dust/minerals of the Earth, not from the drugs of a laboratory. Although there is a time and place for drugs in emergency situations, true healing takes place by replenishment of those components that make up our bodies.
This notice is for any corporate/legal fiction governmental agency and their non-legal fiction employees seeking either intentionally or in ignorance to violate Constitution Protections. (Ref: U.S.C. Title 42 (1983) & https://www.uscfc.uscourts.gov/; https://www.uscfc.uscourts.gov/sites/default/files/Complaint%20Fillable%20Form_2.pdf)
Declaration of Independence (The Sole Mandate of American Government):
We hold these truths to be self-evident, that all men are created equal, that they are endowed by their Creator with certain unalienable Rights, that among these are Life, Liberty and the pursuit of Happiness.–That to secure these rights, Governments are instituted among Men,…
Amendment One (No Commercial Limitation on the Freedom of Speech):
Congress shall make no law respecting an establishment of religion, or prohibiting the free exercise thereof; or abridgng the freedom of speech, or of the press;…
Commentary by Thomas E. Levy, MD, JD (OMNS) Part 1: (OMNS) Probably never before in history has anything or any event mixed fact, fiction, fear, and confusion like the COVID-19 [fake] pandemic of 2019-2020. Political and medical “experts” have been in abundance, primarily regurgitating the same message as though it was something new every time they get interviewed: wash your hands, maintain social distancing, and wear a mask as much as possible. And the public and the news media always take great comfort that an “expert” told them the truth. Trouble is, you can always find another “expert” of equal credentials who will offer a completely contradictory perspective. Understandably, this generates much of the fear and confusion noted above.
Convalescent Plasma (improves, may cure)
Convalescent plasma is plasma collected from individuals who have recovered from an infectious disease resulting in the formation of antibodies. Depending on the severity of COVID-19 infection and the inherent immune capacity in a given patient, the transfusion of convalescent plasma from recovered COVID-19 patients has nearly always significantly reduced the viral load and clinically improved the patient. When the viral load is lowered dramatically, a clinical cure can be expected. A significantly improved survival rate has been seen in COVID-19 patients who have received convalescent plasma therapy. [32,33]
Chloroquine and Hydroxychloroquine (prevents, improves, cures)
I have had the opportunity to see clear-cut and dramatically positive clinical responses in six individuals with rapidly evolving symptoms consistent with fulminant COVID-19 infection treated with oral chloroquine phosphate. In these individuals (ranging from 35 to 65 years of age), therapy was initiated when breathing was very already very difficult and continuing to worsen. In all six, significant improvement in breathing was seen within about four hours after the first dose, with a complete clinical recovery seen after about an average of three days. The oldest individual had a pulse oximeter reading of 80 before the first dose of chloroquine, and the reading improved to 94 after about four hours as the labored breathing eased. The rapidity with which the shortness of breath evolved in all these individuals strongly suggested that respiratory failure secondary to COVID-19-induced acute respiratory distress syndrome was imminent. The chloroquine dosing was continued for several days after complete clinical resolution to prevent any possible clinical relapse. While a large, definitive study on chloroquine and COVID-19 remains to be completed, there is already a great deal of published evidence supporting its effectiveness and overall safety. [34,35] Also, a recent clinical trial demonstrated that hydroxychloroquine given with azithromycin eradicated or significantly decreased measured viral load in respiratory swabs. 
Both chloroquine and hydroxychloroquine are old drugs that are very safe at the doses shown to be effective in treating COVID-19, and they are both recognized as having significant nonspecific antiviral properties. Also, chloroquine, and probably hydroxychloroquine as well, are zinc ionophores, [37,38] which is likely the reason why they have such significant antiviral properties. As noted above in the discussion on zinc, agents that greatly facilitate zinc transport inside virus-infected cells rapidly accelerate virus destruction and clinical resolution of the viral infection. Many clinicians now feel that chloroquine and hydroxychloroquine therapy for COVID-19 and other viruses is optimized by concomitant zinc administration. [39,40] Certainly, there is no good reason to avoid taking zinc with these agents.
As might be expected, drugs as potently antiviral to COVID-19 as chloroquine and hydroxychloroquine would be expected to be effective preventive agents as well, particularly in the setting where exposure is known or strongly suspected to have taken place, or in a setting where repeated and substantial exposure will reliably occur, as in COVID-19-treating hospitals. [41,42] Many front-line health care workers are on such preventive protocols. But many of the physicians who are taking one of these agents to prevent COVID-19 infection are still resistant to giving it to infected patients. This is difficult to logically reconcile if patient welfare is of the uppermost concern.
Radiotherapy (improves, cures)
In a recent pilot trial at Emory University, five nursing home patients hospitalized with COVID-19 were given a single treatment of low-dose radiotherapy over the lungs. All five patients had radiographic evidence of pneumonia and required supplemental oxygen. All five were felt to be deteriorating from a clinical perspective. The radiotherapy consisted of a 10- to 15-minute application of 1.5 Gy (150 rads). Four of the five patients were noted to have a rapid improvement in their breathing, and clinical recovery was seen to occur between 3 and 96 hours post-irradiation.
While many supplement regimens can be used for COVID-19 prevention, such regimens should include at a minimum vitamin C, vitamin D, magnesium chloride, and zinc. Any of many additional quality nutrient and antioxidant supplements can be added as desired, largely dependent on expense and personal preference.
Nebulizations of powerful antipathogen agents, especially hydrogen peroxide, can readily prevent respiratory viral infections like COVID-19 from taking hold, and initiating such nebulizations even after an infection has been contracted will still make a substantial contribution to a more rapid and complete recovery.
As noted earlier, interventions such as ozone and ultraviolet blood treatments have the potential to be effective monotherapies, although it is always a good idea to accompany such treatments with the baseline supplementation regimen and nebulizations as mentioned above.
In the hospitalized setting, intravenous vitamin C and dexamethasone should always be part of the treatment regimen. Nebulizations with hydrogen peroxide and budesonide can accelerate recovery substantially. Also, patients already on ventilator support should always be given vitamin C and dexamethasone along with these nebulizations in addition to anything else felt to be indicated by the attending physician.
Low doses of hydroxychloroquine or chloroquine along with zinc should always be given in the setting of high-risk exposure. Azithromycin can be taken with these agents as well. Higher doses of these agents should always be part of any regimen in the treatment of a suspected or diagnosed COVID-19 patient, whether asymptomatic or already in the hospital.
While the politics of the COVID-19 pandemic are beyond the scope and aim of this article, there remain no valid medical reasons for not using any of the agents or interventions itemized above for either preventing or treating COVID-19 patients. Furthermore, many combinations of these treatments can be applied, depending on their availability and the clinical status of a given patient. Traditional medicine insists on “proof” of any therapy before it is used routinely, even though this standard of proof is never actually obtained for many of the usual prescription drug approaches to infections and other diseases. When an agent is inexpensive, virtually harmless, and with substantial evidence of providing benefit, there is no justification for a physician to refuse or even actively block its administration to a patient otherwise assured of prolonged suffering and likely death (as with hospitalized COVID-19 patients on ventilation support).
With the treatment options available, there is no good reason for most people to even contract COVID-19, and there is certainly no good reason for anyone to die from this virus, much less have a prolonged clinical course of infection with a great deal of needless suffering.
Please note: None of the information in this article is intended to be utilized by anyone as direct medical advice. Rather, the article is intended only to make the reader aware of other treatment possibilities and documented scientific information that can be further discussed with a chosen health care professional.
(Cardiologist and attorney Thomas E. Levy is the author of a number of books, including Curing the Incurable: Vitamin C, Infectious Diseases, and Toxins; Primal Panacea; and Stop America’s #1 Killer. His email is email@example.com).
- Levy T (2011) Primal Panacea, Henderson, NV: MedFox Publishing. ISBN-13: 978-0983772804.
- Marik P, Khangoora V, Rivera R et al. (2017) Hydrocortisone, vitamin C, and thiamine for the treatment of severe sepsis and septic shock: a retrospective before-after study. Chest 151:1229-1238. https://pubmed.ncbi.nlm.nih.gov/27940189
- Levy T (2002) Curing the Incurable. Vitamin C, Infectious Diseases, and Toxins, Henderson, NV: MedFox Publishing. ISBN-13: 978-0977952021
- Gonzalez M, Berdiel M, Miranda-Massari J et al. (2016) High dose intravenous vitamin C treatment for Zika fever. Journal of Orthomolecular Medicine Volume 31. https://www.researchgate.net/publication/309478186_High_Dose_Intravenous_Vitamin_C_Treatment_for_Zika_Fever
- Marcial-Vega V, Gonzalez-Terron G, Levy T (2015) Intravenous ascorbic acid and hydrogen peroxide in the management of patients with Chikungunya. Bulletin of the Medical Association of Puerto Rico 107:20-24. https://pubmed.ncbi.nlm.nih.gov/26035980
- Gonzalez M, Berdiel M, Duconge J et al. (2018) High dose intravenous vitamin C and influenza: a case report. Journal of Orthomolecular Medicine Volume 33. https://isom.ca/article/high-dose-vitamin-c-influenza-case-report
- Frontline COVID-19 Critical Care Alliance (2020) https://covid19criticalcare.com
- Grant W, Lahore H, McDonnell S et al. (2020) Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths. Nutrients 12:988. https://pubmed.ncbi.nlm.nih.gov/32252338
- Dancer R, Parekh D, Lax S et al. (2015) Vitamin D deficiency contributes directly to the acute respiratory distress syndrome (ARDS). Thorax 70:617-624. https://pubmed.ncbi.nlm.nih.gov/25903964
- Qiu X, Kroeker A, He S et al. (2016) Prophylactic efficacy of quercetin 3-β-O-D-glucoside against Ebola virus infection. Antimicrobial Agents and Chemotherapy 60:5182-5188. https://pubmed.ncbi.nlm.nih.gov/27297486
- Levy T (2019) Magnesium, Reversing Disease Henderson, NV: MedFox Publishing. ISBN-13: 978-0998312408.
- Cepero S, Weiser M (2016) Advances of Ozone Therapy in Medicine and Dentistry. http://www.ozonetherapiesgroup.com
- Rowen R, Robins H, Carew K et al. (2016) Rapid resolution of hemorrhagic fever (Ebola) in Sierra Leone with ozone therapy. African Journal of Infectious Diseases 10:49-54. https://journals.athmsi.org/index.php/AJID/article/view/3578/2261
- Oliver T, Murphy D (1920) Influenzal pneumonia: the intravenous injection of hydrogen peroxide. The Lancet Feb 21, pp. 432-433. https://9gurus.com/wp-content/uploads/2020/03/090428.1920.Lancet.H202-Flu.pdf
- Caruso A, Del Prete A, Lazzarino et al. (2020) Might hydrogen peroxide reduce the hospitalization rate and complications of SARS-CoV-2 infection? Infection Control & Hospital Epidemiology Apr 22, online ahead of print. https://pubmed.ncbi.nlm.nih.gov/32319881
- Caruso A, Del Prete A, Lazzarino A (2020) Hydrogen peroxide and viral infections: a literature review with research hypothesis definition in relation to the current COVID-19 pandemic. Medical Hypotheses Jun 1, online ahead of print. https://pubmed.ncbi.nlm.nih.gov/32505069
- Memar M, Yekani M, Alizadeh N, Baghi H (2019) Hyperbaric oxygen therapy: antimicrobial mechanisms and clinical application for infections. Biomedicine & Pharmacotherapy 109:440-447. https://pubmed.ncbi.nlm.nih.gov/30399579
- Yamanel L, Kaldirim U, Oztas Y et al. (2011) Ozone therapy and hyperbaric oxygen treatment in lung injury in septic rats. International Journal of Medical Sciences 8:48-55. https://pubmed.ncbi.nlm.nih.gov/21234269
- Rowen R (1996) Ultraviolet blood irradiation therapy (photo-oxidation), the cure that time forgot. Int J Biosocial Med Res 14:115-132. http://drferchoff.com/files/ubiarticle.pdf
- Zhu Z, Guo Y, Yu P et al. (2019) Chlorine dioxide inhibits the replication of porcine reproductive and respiratory syndrome virus by blocking viral attachment. Infection, Genetics and Evolution 67:78-87. https://pubmed.ncbi.nlm.nih.gov/30395996
- Kaly-Kullai K, Wittmann M, Noszticzius Z, Rosivall L (2020) Can chlorine dioxide prevent the spreading of coronavirus or other viral infections? Medical hypotheses. Physiology International 107:1-11. https://pubmed.ncbi.nlm.nih.gov/32208977
- Over 100 Recoverded from Covid-19 with CDS by Physicians of the AEMEMI (2020) https://lbry.tv/@Kalcker:7/100-Recovered-Aememi-1:7
- Determination of the Effectiveness of Oral Chlorine Dioxide in the Treatment of COVID 19 (2020) https://clinicaltrials.gov/ct2/show/NCT04343742
- Singh A, Majumdar S, Singh R, Misra A (2020) Role of corticosteroid in the management of COVID-19: a systemic review and a clinician’s perspective. Diabetes & Metabolic Syndrome 14:971-978. https://pubmed.ncbi.nlm.nih.gov/32610262
- Villar J, Ferrando C, Martinez D et al. (2020) Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomized controlled trial. The Lancet. Respiratory Medicine 8:267-276. https://pubmed.ncbi.nlm.nih.gov/32043986
- Szefler S, Eigen H (2002) Budesonide inhalation suspension: a nebulized corticosteroid for persistent asthma. The Journal of Allergy and Clinical Immunology 109:730-742. https://pubmed.ncbi.nlm.nih.gov/11941331
- Saito M, Kikuchi Y, Lefor A, Hoshina M (2017) High-dose nebulized budesonide is effective for mild asthma exacerbations in children under 3 years of age. European Annals of Allergy and Clinical Immunology 49:22-27. https://pubmed.ncbi.nlm.nih.gov/28120603
- Dai Q, Duan C, Liu Q, Yu H (2017) Effect of nebulized budesonide on decreasing the recurrence of allergic fungal rhinosinusitis. American Journal of Otolaryngology 38:321-324. https://pubmed.ncbi.nlm.nih.gov/28185668
- McIntire A, Harris S, Whitten J et al. (2017) Outcomes following the use of nebulized heparin for inhalation injury (HIHI Study). Journal of Burn Care & Research 38:45-52. https://pubmed.ncbi.nlm.nih.gov/27532613
- Rello J, Rouby J, Sole-Lleonart C et al. (2017) Key considerations on nebulization of antimicrobial agents to mechanically ventilated patients. Clinical Microbiology and Infection 23:640-646. https://pubmed.ncbi.nlm.nih.gov/28347790
- Turpeinen M, Nikander K (2001) Nebulization of a suspension of budesonide and a solution of terbutaline into a neonatal ventilator circuit. Respiratory Care 46:43-48. https://pubmed.ncbi.nlm.nih.gov/11175237
- Bloch E, Shoham S, Casadevall A et al. (2020) Deployment of convalescent plasma for the prevention and treatment of COVID-19. Journal of Clinical Investigation 130:2757-2765. https://pubmed.ncbi.nlm.nih.gov/32254064
- Brown B, McCullough J (2020) Treatment for emerging viruses: convalescent plasma and COVID-19. Transfusion and Apheresis Science 59:102790. https://pubmed.ncbi.nlm.nih.gov/32345485
- Cortegiani A, Ingoglia G, Ippolito M et al. (2020) A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. Journal of Critical Care 57:279-283. https://pubmed.ncbi.nlm.nih.gov/32173110
- Devaux C, Rolain J, Colson P, Raoult D (2020) New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? International Journal of Antimicrobial Agents 55:105938. https://pubmed.ncbi.nlm.nih.gov/32171740
- Gautret P, Lagier J, Parola P et al. (2020) Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International Journal of Antimicrobial Agents Mar 20, 105949. https://pubmed.ncbi.nlm.nih.gov/32205204
- Xue J, Moyer A, Peng B et al. (2014) Chloroquine is a zinc ionophore. PLoS One 9:e109180. https://pubmed.ncbi.nlm.nih.gov/25271834
- Xu Y, Xiao G, Liu L, Lang M (2019) Zinc transporters in Alzheimer’s disease. Molecular Brain 12:106. https://pubmed.ncbi.nlm.nih.gov/31818314
- Derwand R, Scholz M (2020) Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win today’s battle against COVID-19? Medical Hypotheses May 6, 142:109815. https://pubmed.ncbi.nlm.nih.gov/32408070
- Shittu M, Afolami O (2020) Improving the efficacy of chloroquine and hydroxychloroquine against SARS-CoV-2 may require zinc additives-a better synergy for future COVID-19 clinical trials. Le Infezioni in Medicina 28:192-197. https://pubmed.ncbi.nlm.nih.gov/32335560
- Shah S, Das S, Jain A et al. (2020) A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19 (COVID-19). International Journal of Rheumatic Diseases 23:613-619. https://pubmed.ncbi.nlm.nih.gov/32281213
- Huang M, Tang T, Pang P et al. (2020) Treating COVID-19 with chloroquine. Journal of Molecular Cell Biology 12:322-325. https://pubmed.ncbi.nlm.nih.gov/32236562
The views expressed in this article are the author’s and not necessarily those of the Orthomolecular Medicine News Service or all members of its Editorial Board. OMNS invites alternative viewpoints. Submissions may be sent directly to Andrew W. Saul, Editor, at the email contact address below.
Nutritional Medicine is Orthomolecular Medicine
Orthomolecular medicine uses safe, effective nutritional therapy to fight illness. For more information: http://www.orthomolecular.org
The peer-reviewed Orthomolecular Medicine News Service is a non-profit and non-commercial informational resource.
Editorial Review Board:
Ilyès Baghli, M.D. (Algeria)
Ian Brighthope, MBBS, FACNEM (Australia)
Gilbert Henri Crussol, D.M.D. (Spain)
Carolyn Dean, M.D., N.D. (USA)
Damien Downing, M.B.B.S., M.R.S.B. (United Kingdom)
Martin P. Gallagher, M.D., D.C. (USA)
Michael J. Gonzalez, N.M.D., D.Sc., Ph.D. (Puerto Rico)
William B. Grant, Ph.D. (USA)
Tonya S. Heyman, M.D. (USA)
Suzanne Humphries, M.D. (USA)
Ron Hunninghake, M.D. (USA)
Robert E. Jenkins, D.C. (USA)
Bo H. Jonsson, M.D., Ph.D. (Sweden)
Jeffrey J. Kotulski, D.O. (USA)
Peter H. Lauda, M.D. (Austria)
Thomas Levy, M.D., J.D. (USA)
Alan Lien, Ph.D. (Taiwan)
Homer Lim, M.D. (Philippines)
Stuart Lindsey, Pharm.D. (USA)
Victor A. Marcial-Vega, M.D. (Puerto Rico)
Charles C. Mary, Jr., M.D. (USA)
Mignonne Mary, M.D. (USA)
Jun Matsuyama, M.D., Ph.D. (Japan)
Joseph Mercola, D.O. (USA)
Jorge R. Miranda-Massari, Pharm.D. (Puerto Rico)
Karin Munsterhjelm-Ahumada, M.D. (Finland)
Tahar Naili, M.D. (Algeria)
W. Todd Penberthy, Ph.D. (USA)
Dag Viljen Poleszynski, Ph.D. (Norway)
Selvam Rengasamy, MBBS, FRCOG (Malaysia)
Jeffrey A. Ruterbusch, D.O. (USA)
Gert E. Schuitemaker, Ph.D. (Netherlands)
T.E. Gabriel Stewart, M.B.B.CH. (Ireland)
Hyoungjoo Shin, M.D. (South Korea)
Thomas L. Taxman, M.D. (USA)
Jagan Nathan Vamanan, M.D. (India)
Garry Vickar, M.D. (USA)
Ken Walker, M.D. (Canada)
Raymond Yuen, MBBS, MMed (Singapore)
Anne Zauderer, D.C. (USA)
Andrew W. Saul, Ph.D. (USA), Editor-In-Chief
Editor, Japanese Edition: Atsuo Yanagisawa, M.D., Ph.D. (Japan)
Editor, Chinese Edition: Richard Cheng, M.D., Ph.D. (USA)
Editor, French Edition: Vladimir Arianoff, M.D. (Belgium)
Robert G. Smith, Ph.D. (USA), Associate Editor
Helen Saul Case, M.S. (USA), Assistant Editor
Michael S. Stewart, B.Sc.C.S. (USA), Technology Editor
Jason M. Saul, JD (USA), Legal Consultant
Comments and media contact: firstname.lastname@example.org OMNS welcomes but is unable to respond to individual reader emails. Reader comments become the property of OMNS and may or may not be used for publication.
Categories: SILVER BULLETIN e-NEWS MAGAZINE